<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>21(1)</volume><submitter>Uchiyama K</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The role of IL-12/23 in the pathogenesis of ulcerative colitis (UC) is unclear. We analyzed mucosal IL-12/23 expression and its relationship with endoscopic severity, histological activity, and UC relapse.&lt;h4>Methods&lt;/h4>Rectal biopsies were collected from 70 UC patients with clinical remission. IL-12, IL-23, IFN-γ, IL-17A, and IL-17F mRNA expression was measured by real-time PCR. Endoscopic severity and histological activity were evaluated using the Mayo endoscopic subscore (MES) and the Geboes score, respectively.&lt;h4>Results&lt;/h4>The longest follow-up period was 51 months. Thirty-four patients relapsed during the study period. Samples from these subsequently relapsed patients formed the "relapse" group, while those from patients that did not relapse formed the "remissio</pubmed_abstract><journal>BMC gastroenterology</journal><pagination>122</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7968323</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis.</pubmed_title><pmcid>PMC7968323</pmcid><pubmed_authors>Naito Y</pubmed_authors><pubmed_authors>Ishikawa T</pubmed_authors><pubmed_authors>Takagi T</pubmed_authors><pubmed_authors>Toyokawa Y</pubmed_authors><pubmed_authors>Kamada K</pubmed_authors><pubmed_authors>Kashiwagi S</pubmed_authors><pubmed_authors>Uchiyama K</pubmed_authors><pubmed_authors>Hotta Y</pubmed_authors><pubmed_authors>Mizushima K</pubmed_authors><pubmed_authors>Kajiwara-Kubota M</pubmed_authors><pubmed_authors>Konishi H</pubmed_authors><pubmed_authors>Itoh Y</pubmed_authors><pubmed_authors>Kishimoto M</pubmed_authors><pubmed_authors>Tanaka M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis.</name><description>&lt;h4>Background&lt;/h4>The role of IL-12/23 in the pathogenesis of ulcerative colitis (UC) is unclear. We analyzed mucosal IL-12/23 expression and its relationship with endoscopic severity, histological activity, and UC relapse.&lt;h4>Methods&lt;/h4>Rectal biopsies were collected from 70 UC patients with clinical remission. IL-12, IL-23, IFN-γ, IL-17A, and IL-17F mRNA expression was measured by real-time PCR. Endoscopic severity and histological activity were evaluated using the Mayo endoscopic subscore (MES) and the Geboes score, respectively.&lt;h4>Results&lt;/h4>The longest follow-up period was 51 months. Thirty-four patients relapsed during the study period. Samples from these subsequently relapsed patients formed the "relapse" group, while those from patients that did not relapse formed the "remissio</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2025-04-22T08:18:20.146Z</modification><creation>2025-04-05T22:29:12.03Z</creation></dates><accession>S-EPMC7968323</accession><cross_references><pubmed>33730998</pubmed><doi>10.1186/s12876-021-01709-5</doi></cross_references></HashMap>